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ABSTRACT Clinical studies of new antitubercular drugs are costly and time-
consuming. Owing to the extensive tuberculosis (TB) treatment periods, the ability
to identify drug candidates based on their predicted clinical efficacy is vital to accel-
erate the pipeline of new therapies. Recent failures of preclinical models in predict-
ing the activity of fluoroquinolones underline the importance of developing new
and more robust predictive tools that will optimize the design of future trials. Here,
we used high-content imaging screening and pharmacodynamic intracellular (PDi)
modeling to identify and prioritize fluoroquinolones for TB treatment. In a set of
studies designed to validate this approach, we show moxifloxacin to be the most ef-
fective fluoroquinolone, and PDi modeling-based Monte Carlo simulations accurately
predict negative culture conversion (sputum sterilization) rates compared to eight
independent clinical trials. In addition, PDi-based simulations were used to predict
the risk of relapse. Our analyses show that the duration of treatment following cul-
ture conversion can be used to predict the relapse rate. These data further support
that PDi-based modeling offers a much-needed decision-making tool for the TB drug
development pipeline.
KEYWORDS PDi, infectious disease, pharmacodynamics, pharmacokinetics, preclinical
drug studies, tuberculosis
Tuberculosis (TB) caused by Mycobacterium tuberculosis is the leading cause of deathfrom a single infectious agent. The so-called short course treatment of drug-
susceptible TB (2-month intensive phase of rifampin [RIF], isoniazid [INH], pyrazinamide
[PZA], and ethambutol [EMB], followed by 4 months of RIF and INH) (1) remains long,
complex, and expensive, with a relatively high failure rate due to patient noncompli-
ance and drug resistance. Fluoroquinolones were introduced into the regimen for
multidrug-resistant TB (MDR-TB) after demonstration of their in vitro and in vivo
antimycobacterial activity (2–6). They are now considered by the World Health Orga-
nization (WHO) to be a critical component in MDR-TB treatment. Fluoroquinolones are
also administered when patients cannot tolerate the standard regimen (7). However,
fluoroquinolones, especially third generation, are often discussed in terms of a generic
drug class, and the specific choice of fluoroquinolone is generally not specified and is
therefore often based on availability, cost, and national guidelines.
It was anticipated that by introducing fluoroquinolones into drug-susceptible reg-
imens, the treatment period could be reduced by 2 months (from 6 to 4 months) (8).
Clinical trials with moxifloxacin (MXF) produced mixed results, with some displaying
superior activity that would indicate shorter treatment courses (9, 10) but others
displaying little to no acceleration in achieving negative culture conversion (11, 12).
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However, a recent meta-analysis of all clinical data showed a significant improvement
of culture conversion rates in total (13).
Pharmacokinetic/pharmacodynamic (PK/PD) models are useful in evaluating the
length of treatment required by new regimens of anti-TB drugs. Recent clinical trials
have highlighted the concerns of preclinical studies. Animal models show dynamics
that differ from those observed in humans (14, 15), and predicted treatment improve-
ments observed in mice with reformed regimens have often failed to reflect similar
results in clinical settings. For example, murine studies with rifamycins (16–18) over-
predicted the superior activity of higher doses of rifapentine in clinical studies. Simi-
larly, animal studies were interpreted as showing a significant potential for the
reduction in time of TB treatment with MXF (19), suggesting that treatment could
be reduced by 1 month based on the in vivo results (20). However, phase 3 clinical
trials (e.g., REMOX and RIFAQUIN) highlighted that despite the superiority of MXF,
it was insufficient to display relapse-free cure rates observed in 6 months of
conventional TB therapy (11, 21).
We have previously shown that PD data obtained from an in vitro intracellular
(macrophage) M. tuberculosis high-content imaging-based platform, termed intracellu-
lar pharmacodynamics (PDi), can be a powerful tool for predicting the activity of
first-line TB drugs in patients (22). Our platform is capable of defining the killing kinetics
of first line anti-TB drugs against intracellular M. tuberculosis. Building from this previous
work, and using a refined method that allows for extended monitoring of live drug-
exposed intracellular M. tuberculosis, we profile fluoroquinolones here to assess their
antitubercular efficacy. In addition, using these data we performed PDi-based PK/PD
predictions of clinical outcome in terms of culture conversion rates and compare these
values with clinical studies. The data are discussed in the context of the use of
fluoroquinolones toward shortening treatment duration and the value of the PDi-based
approach as a decision-making tool in the drug development of new treatment
therapies.
RESULTS
Fluoroquinolones exhibit comparable rates of kill against intracellular M.
tuberculosis but differ in potency. The efficacy of selected fluoroquinolones against
intracellular M. tuberculosis was initially determined using the described fluorimetric-
based assay (see methods). The intracellular anti-tubercular activity of MXF, levofloxacin
(LVX), norfloxacin (NOX), ofloxacin (OFX), sparfloxacin (SPX), and ciprofloxacin (CIP) was
assessed at a concentration ranges between 0.01 and 100 mg/liter. The kill rate elicited
by each concentration was then calculated as previously described (22). Figure 1
displays the kill rate for each drug’s concentration range. A concentration-effect
relationship using a three-parameter pharmacological model was then determined for
each drug (Fig. 2). This model affords the calculation of pharmacological parameters,
namely, the 50% effective concentration (EC50) and the maximal kill rates for each drug
(Fig. 2a to f). Figure 2g compares the profiles of all drugs where the gray area represents
the kill rate of RIF (a first-line antibiotic) at 25 mg/liter (this concentration was chosen
since it is 1,000-fold the EC50 and is used to determine the Emax [see Materials and
Methods]).
The fluoroquinolones tested displayed variability in potency for their respective
intracellular anti-TB activities. SPX displayed the lowest EC50 (0.051 mg/liter), followed
by MXF, CIP, and LVX (0.238, 0.259, and 0.382 mg/liter, respectively), while OFX and
NOX displayed poor activity with EC50s of 1.414 to 1.705 mg/liter, as shown in Fig. 1 and
2 and in Table S1 in the supplemental material. Of note, although fluoroquinolones
displayed variation in EC50s, the maximal kill rate for all fluoroquinolones was deter-
mined to be comparable (Fig. 2g), which is consistent with the drugs possessing the
same mode of action.
Similar to our previous work with RIF, INH, and EMB (22), the MXF kill rate of M.
tuberculosis grown in culture, termed extracellular, was significantly faster than the kill
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FIG 1 Intracellular (macrophage) M. tuberculosis time-dependent kill profiles of fluoroquinolones. Panels
display time-kill profiles of MXF (a), CIP (b), SPX (c), LVX (d), OFX (e), and NOX (f). M. tuberculosis control
(no drug) data are indicated in black, and RIF data at 25 mg/liter are indicated in red. The data are
means  the standard deviation (SD) derived from multiple independent experiments (n  3) performed
at least in triplicate.
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FIG 2 Concentration-intracellular M. tuberculosis kill rate relationship for selected fluoroquinolones. Open black circles
represent individual kill rates at each concentration for drugs, and the dashed black lines display the three-parameter
pharmacological fit for each drug. (a) MXF; (b) CIP; (c) SPX; (d) LVX; (e) OFX; (f) NOX. (g) Comparison of the profiles of all
drugs. The gray area represents the kill rate of RIF at 25 mg/liter. n  6 in three independent experimental replicates for
each drug.
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rate of MXF against intracellular (macrophage) M. tuberculosis (0.23 h1 extracellular
versus 0.055 h1 intracellular [Fig. S1, and Fig. 1, respectively]).
Determination of the M. tuberculosis growth/kill rate ratio for fluoroquinolo-
nes. The above-described live M. tuberculosis fluorimetry-based assay allowed us to
rapidly determine the kill rate EC50 for the described fluoroquinolones, using a
population-based fluorometric readout of intracellular M. tuberculosis. To define the
maximal killing rate for the fluoroquinolone class at greater resolution and dynamic
range, killing dynamics were measured using an Operetta-based high-content
imaging screen, which can image individual bacilli residing inside macrophages
(Fig. 3).
Figure 3 displays intracellular M. tuberculosis in the absence (Fig. 3a) or presence
(Fig. 3b) of MXF (63 magnification) and shows the maximal kill rate displayed by MXF
(100 mg/liter) compared to RIF at a concentration of 25 mg/liter (Fig. 3c). The maximal
kill rate of both drugs was equivalent and was determined to be approximately
1.8  no-drug control growth rate. This concurs with the maximal kill rate/growth
rate ratio previously reported for RIF (22). Our results demonstrate that despite RIF
being the superior compound, by way of a lower EC50 value (0.019 mg/liter RIF versus
0.238 mg/liter MXF), the kill rate/growth rate ratio of MXF at a maximal concentration
(100 mg/liter) was 1.82, similar to that of RIF at a maximal concentration (Fig. 3 and see
Fig. S2 and S3 in the supplemental material).
PDi modeling predicts culture conversion rates compared to clinical trial data.
MXF data from an Operetta-based high-content imaging screen was modeled and























FIG 3 High-content fluorescent images as acquired from the Operetta (Perkin-Elmer). Fixed macrophages
were infected with M. tuberculosis H37Rv expressing the far-red reporter mCherry after 72 h with no drug
treatment (a) or with 100 mg/liter MXF (b). Orange, H37Rv-mCherry; blue, macrophage nuclei stained
with Hoechst. Scale bar, 50 m. (c) Activity of MXF against intracellular M. tuberculosis (data acquired
from the Operetta via Harmony [Perkin-Elmer]). The red solid line displays the maximal kill rate obtained
by RIF at 25 mg/liter.
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compared to clinical trial data reported in the literature. PDi modeling was performed
for MXF using PD data obtained from the Operetta study. PK data and pulmonary
exposure were calculated for MXF as reported when administered concomitantly with
RIF since all simulations assumed concomitant administration of the two drugs (23, 24).
Epithelial lining fluid (ELF) concentrations were used as a surrogate for pulmonary
exposure and were obtained from the literature as estimated in healthy volunteers (25,
26). In the absence of such ratios in TB patients, we used healthy volunteer data as the
closest possible estimate.
PDi modeling was used to generate COX regression curves. The curves indicate the
percentage of patients achieving culture-negative conversion over time (culture con-
version to negative is defined as 10 CFU/ml in sputum tests) (27).
To compare our predictions with the clinical literature, we used Monte Carlo
simulations to generate hypothetical treatment outcomes when using the same regi-
mens previously used in clinical trials. PDi modeling predicted that within 8 weeks 96%
of the patients would achieve culture-negative status when INH or ETB is replaced with
400 mg of MXF (the PK/PD properties of partner drugs are based on reference 22, as
shown in Table S1). Our results concur with several clinical studies, as displayed in Table
S2 and Fig. 4. PDi-based odds ratios were estimated to be 1.726 (confidence interval
[CI]  1.216 to 2.45), which is comparable to reported or calculated ratios from clinical
literature data (Table S2, Fig. 4). PDi prediction of culture conversion rates for MXF
containing regimens seems to be marginally faster than that observed in the most
comprehensive study (11). However, our prediction is in line with the median of eight
different clinical studies over 8 weeks (Fig. 4b and Table S2).
Table S3 displays the sensitivity analysis of the PDi modeling (see Materials and
Methods), which indicates that the maximal kill rate (Emax) of MXF is the most influential
parameter upon bacillary clearance. The second most significant parameter is the initial
intracellular burden the patient presents at the clinic, concurring with previous clinical
studies (28, 29), followed by the PK parameters and MXF drug potency (EC50). The
potency and PK parameters of RIF ranked lower than MXF parameters in our sensitivity
analysis. The parameters for other partner drugs (INH, EMB, or PZA) played a negligible
role in the overall outcome of the simulations.
At higher concentrations, LVX is predicted to be as effective as MXF at killing
M. tuberculosis. Since the PDi model is ultimately based on pulmonary exposure (i.e.,
concentration in ELF), we compared the overall PK properties and the ELF exposures of
MXF, CIP, and LVX (Table S4). Simulations predict MXF to have superior PK properties
due to its relatively high AUC level in the plasma, and it displays the highest accumu-
lation in the ELF. Table S4 shows that LVX at a higher dose of 750 mg/day would
achieve a pulmonary PK profile very similar to that observed for MXF at 400 mg/day.
Assuming linear PK for LVX, 500 mg/day is expected to achieve ELF exposure inferior to
400 mg/day of MXF. At a 1,000-mg dose, LVX has a comparable ELF AUC value
(221.7 mg · h/liter) compared to a standard dose of MXF of 400 mg/day (173.1 mg ·
h/liter). Systematic PK parameters were chosen from previously reported data (per
Table S4).
Simulating various doses of LVX and MXF and integrating this with our imaging-
based PDi data reveals that an increase of LVX from 500- to 1,000-mg results in a
remarkable improvement in activity (88% of patients were predicted to achieve neg-
ative culture conversion at 8 weeks with 500 mg of LVX versus 93% of patients
predicted to achieve negative culture conversion at 8 weeks with 1,000 mg of LVX; Fig.
5). In contrast, we predict that an increase in the dose of MXF from 400 to 800 mg
would result in a more modest improvement (95% of patients would achieve culture-
negative status with 400 mg of MXF versus 96% with 800 mg of MXF) (Fig. 5).
Using PDi-based modeling to predict TB treatment duration and risk of re-
lapse. As described, fluoroquinolones have been clinically assessed in efforts to shorten
standard therapy (7, 20, 30). We believe culture conversion is related to relapse rates
and hypothesize that after culture conversion, further therapy is required to kill
hidden/recalcitrant bacilli populations. Figure 6 displays how many patients would
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hypothetically be at risk of disease relapse when comparing the standard regimen to
a MXF arm for 4 or 5 months. We hypothesize that this is directly related to the time
taken to culture convert during treatment, which will differ between all patients. As
shown, 6% of patients in the standard treatment arm will culture convert late (80 days
before end of treatment) and therefore not receive treatment for 80 days postconver-
sion compared to 15% in the 4-month MXF and 4% in the 5-month MXF arm.
DISCUSSION
PDi modeling has previously been utilized for the prediction of treatment outcome
for TB patients receiving standard or high-dose RIF therapy (22, 31) Here, we used a
similar approach to predict treatment outcomes using fluoroquinolone-based regi-
FIG 4 Culture conversion rates and forest plot of odds ratios. (a) Observed culture conversion rates from
patients treated with MXF, RIF, EMB, and PZA for 4 months in a clinical study by Gillespie et al. (11) (solid
black line) compared to our PDi prediction for the same dosing regimen over the same duration (dashed
blue line). (b) Forest plot showing odds ratios from eight clinical studies (13) compared to odds ratio
calculated using our PDi-based Monte Carlo simulations. The gray area represents the range of PDi
prediction.
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mens. Fluoroquinolones have been considered by many to be a means to shorten the
current standard therapy (7, 20, 30).
We have presented intracellular killing kinetics for six different fluoroquinolone
drugs assessed using two methods. The first method is useful for rapid ranking of the
potency of the various drugs resulting in concentration-effect relationships (Table S1).
FIG 5 PDi predictions of culture conversion rates for MXF (400 mg daily, 4 months, dashed blue line)
versus LVX (1,000 mg daily, 4 months, solid black line), LVX (500 mg daily, 4 months, dashed red line), and
MXF (800 mg daily, dashed green line).
FIG 6 Predicted or observed relapse rates. The percentages of patients predicted to relapse (based on
late culture conversion status) (black bars) compared to observed relapse rates, as observed in Gillespie
et al. (11) (gray bars), are shown. The observed relapse rates are based on both MXF arms in the clinical
study. 4m, 4 months; 6m, 6 months; 5m, 5 months (data for 5-month MXF are not available).
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This allows for the identification of the best candidates for further analysis. The results
demonstrated that four of the six fluoroquinolones have similar potencies (MXF, LVX,
CIP, and SPX). Despite RIF, our control compound, being superior overall, MXF displayed
a similar maximal kill rate in both the live fluorimetry and the fixed Operetta assay.
However, patients treated with a 4-month regimen containing MXF showed higher
rates of disease relapse despite achieving faster culture conversion in comparison to
standard treatments (11). MXF, however, has superior PK properties compared to a
standard regimen of RIF (which is currently dosed suboptimally), especially in its
accumulation in the lung and ELF. The high accumulation levels compensate for the
lower potency compared to RIF and leads to better overall effect in Monte Carlo
simulations, predicting a median culture conversion time of 31 days compared to
56 days for standard treatment.
Our intracellular data were in agreement with data from a murine macrophage
study, showing that NOX and OXF are significantly less potent than MXF (32). While SPX
displayed the lowest EC50, cytotoxicity was observed, as reported in the literature (33);
therefore, it was eliminated from further investigation. MXF, CIP, and LVX showed
similar potency and maximal kill rates. CIP displayed an EC50 similar to that for MXF in
our study, but at 500 mg it has 10-fold lower exposure in the ELF compared to MXF at
400 mg (25). Therefore, only MXF and LVX were considered further in our analyses. A
1,000-mg dose of LVX has a comparable ELF AUC value (221.7 mg · h/liter) compared
to a standard dose of MXF of 400 mg/day (173.1 mg · h/liter, Table S4) and that at this
higher dose, the clinical efficacy of LVX, in terms of culture conversion rates, is predicted
by the PDi-based modeling to be comparable to MXF (Fig. 5). This observation is
consistent with a recent clinical study comparing MXF (400 mg) to high-dose (750 mg)
LVX, demonstrating that both regimens result in a similar clinical outcome (34, 35).
These data support that, in the absence of any safety concerns, LVX should be further
tested at higher doses.
Similar to the work described previously (22), we show that it is the intracellular kill
rate of MXF that limits the reduction in CFU burden, even when the intracellular
population represents just 5% of the overall population (within our model 95%
represented by extracellular M. tuberculosis). Figure S4 displays the biexponential
nature of CFU reduction which, in our simulation, is a direct result of having two
separate populations (extracellular and intracellular) (Fig. S4).
That our PDi-based modeling approach (using short-term measurements of intra-
cellular M. tuberculosis killing) is able to predict long-term clinical responses is perhaps
not surprising when it is considered that the majority of patients (ca. 80%) culture
convert within ca. 8 weeks of treatment (36). We have previously shown that clinical
biphasic treatment responses can be explained by an initial reduction in extracellular M.
tuberculosis, followed by a second, slower phase of bacillary clearance that largely
corresponds to the killing dynamics of intracellular (macrophage) M. tuberculosis (22,
37). The duration of this second slower bacillary clearance rate is typically 5 to 6 weeks.
Therefore, the PDi-based modeling approach should be viewed as a predictive tool to
determine the clinical response over this shorter time frame, which is nonetheless a
critical clinical feature to assess drug efficacy. Clearly, the PDi-based modeling approach
does not take into account the response to treatment of slow growing/dormant bacilli,
which are thought to be relevant to TB treatment outcome (38). However, given the
strong agreement in the PDi-based modeling with observed clinical bacillary clearance
responses, it is our view that these important PD and PK considerations are more
relevant in terms of predicting microbiological treatment outcomes and potentially
treatment relapse rates. As described, this study proposes that a useful proxy to
estimating disease relapse is the treatment duration after culture conversion, and
therefore knowledge of bacillary clearance rates for drugs and drug combinations can
be used to inform treatment outcome and relapse rates.
Should MXF be introduced to the standard treatment? Incorporating MXF into
treatment regimens results in faster clearance rates of bacilli compared to standard
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treatment in eight different clinical studies (13). As mentioned earlier, Gillespie et al.
showed that a 4-month MXF-based treatment results in a higher relapse rate (11, 21).
Superior culture conversion results indicate that relapse rates should be lower in the
MXF arm. PDi simulations can accurately predict the percentage of patients reaching
culture-negative status compared to observed clinical findings (Table S2). In addition,
sensitivity analysis (Table S3) indicates that MXF in these regimens is the main driver of
activity in combination treatments, and its effect significantly supersedes that of RIF,
thus explaining the accelerated clearance of bacilli when MXF is introduced to the drug
regimen.
However, the culture conversion rates in clinical findings did not predict the high
relapse rate in the MXF arm that was reported in Gillespie et al. in 2014 (11). One
explanation for this disparity between bacilli clearance rates and disease relapse could
be related to the length of time treatment is received after achieving negative culture
conversion. This will vary between individual patients. We hypothesize that each
patient requires treatment exceeding 80 days following culture conversion. For exam-
ple, according to our PDi predictions, in the 4-month MXF arm 12 to 17% of patients
will be at risk for relapse since they will culture convert late and receive treatment for
80 days after culture converting (Fig. 6). In contrast, only 7% will be at risk of relapse
in the standard 6-month arm. The remaining 93% will remain on treatment for 80
days after culture conversion. We have suggested an 80-day duration after culture
conversion because this is the duration that predicts 15% relapse rate, which agrees
with relapse rates observed in the Gillespie et al. clinical trial with MXF-containing
regimens. This correlation between delayed culture conversion and relapse rate has
previously been suggested (39), although this seems to be with limitations since many
patients with delayed culture conversion might still have favorable outcomes. Based on
our data and simulations, introducing MXF into the standard regimen could lead to a
reduced treatment period, e.g., from 6 to 5 months. These findings further support the
notion of individualized therapy, where patients with late culture conversion could
receive treatment for longer durations than those with early culture conversion (40).
Conclusions. Our preclinical model may offer an insight into the performance of
compounds with the overall aim of reducing the TB treatment period down from 6
months. By adding MXF into the regimen, we predicted the treatment outcome and
could offer recommendations for its use in the clinic. Although results from previous
clinical trials were disappointing when substituting MXF into the standard regimen, it
is a well-tolerated compound with high antimycobacterial and favorable ELF properties.
Based on our modeling, MXF and LVX have the potential to shorten the treatment
period, and our data aligns with independent clinical results. The individual time frame
in which a patient converts to a culture-negative status is particularly important when
determining treatment duration, and a more individual-based therapy would be highly
beneficial in reducing treatment duration and potentially in reducing relapse rates.
MATERIALS AND METHODS
Chemical compounds. The fluoroquinolones moxifloxacin (MXF), levofloxacin (LVX), norfloxacin
(NOX), ofloxacin (OFX), sparfloxacin (SPX), and ciprofloxacin (CIP) were purchased from Sigma, UK. All
compounds were made up in dimethyl sulfoxide (Sigma).
Mycobacterial strain, growth, and macrophage growth. M. tuberculosis H37Rv expressing the
far-red reporter mCherry was used in this study (H37Rv-mCherry) (22). Aliquots of H37Rv-mCherry was
precultured aerobically at 37°C in Middlebrook 7H9 broth (Difco) supplemented with 0.05% (vol/vol)
Tween 80 (Sigma), 0.2% (vol/vol) glycerol, 10% oleic acid-albumin-dextrose-catalase (OADC; 7H9), and
50 mg/liter hygromycin (Sigma) with magnetic stirrers. THP-1 cells were routinely cultured in RPMI 1640
supplemented with L-glutamine, NaHCO3 (Gibco), and 10% heat-inactivated fetal bovine serum (HI-FBS;
Gibco) at 37°C and 5% CO2.
Macrophage infection assay. THP-1 cells were differentiated in Perkin-Elmer CellCarrier-96 plates,
seeded at 5  105 cells per well, and differentiated for 72 h in supplemented RPMI 1640 and 100 ng/ml
phorbol 12-myristate 13-acetate (PMA; Sigma) at 37°C and 5% CO2. Differentiated THP-1 cells were
infected with H37Rv-mCherry in suspension at a multiplicity of infection of 1:5 in FluoroBrite Dulbecco
modified Eagle medium (DMEM) supplemented with 10% HI-FBS and L-glutamine for 24 h at 37°C. For
optimal macrophage environment, each 96-well plate was covered with a Breath-EASIER sealing mem-
brane (Sigma) to allow gaseous exchange but maintaining containment level 3 safety regulations. This
has been refined from our previous work, improving the THP-1 cell growth conditions. After 24 h, the
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cells were washed, and the drugs at the required concentrations were added in FluoroBrite DMEM to a
total volume of 200 l. Infected cells were incubated for up to 144 h.
Extracellular-grown (planktonic) M. tuberculosis kill kinetics were obtained by incubating M. tubercu-
losis H37Rv in the presence of test drug, followed by plating to obtain CFU. M. tuberculosis was cultured
at 37°C in Middlebrook 7H9 broth (Difco) supplemented with 0.05% (vol/vol) Tween 80 (Sigma), 0.2%
(vol/vol) glycerol, 10% OADC (7H9), and 50 mg/liter hygromycin (Sigma) with magnetic stirrers to the
mid-log-growth phase before 2-fold dilutions of test drug ranging from 15,360 to 30 ng/ml were added.
A sample of culture was plated at 0 h before drug was added to obtain the initial bacterial count. After
the addition of drug, 2-ml aliquots of bacterial culture with magnetic stirrers were incubated at 37°C in
complete media. At defined time intervals of 24, 48, 72, 96, and 168 h, aliquots were pelleted to remove
drug. These were serially diluted in PBS, plated on Middlebrook 7H11 agar, and incubated at 37°C in 5%
CO2 for 28 days. The Miles Misra method was used to determine CFU (41).
Fluorometer drug screening, high-content image acquisition, and data analysis. Data were
generated from multiple independent experiments (n  3), all performed at least in triplicate, and data
were produced via two methods. First, each plate was screened every 24 h for fluorescence using a
Varioskan (LUX multimode reader; Thermo Scientific) at an excitation of 578 nm and emission of 610 nm,
thus producing “live” fluorometer readouts. In addition, plates were fixed with 5% paraformaldehyde
(Sigma) for 2 h for imaging using an Operetta (Perkin-Elmer) with a 60 High NA objective, as described
previously (22).
The Z=-factor for the Varioskan assay, calculated using an equation reported by Zhang et al. (42), was
0.57 for the data set.
Unlike the Operetta-based high content imaging screen, maximum kill rates cannot be calculated
from the fluorometer. Upon bacillus death, the measured linear response of M. tuberculosis to a
compound eventually plateaus, limiting the dynamic range of the assay.
Data analysis and modeling. Fluoroquinolone activity was ranked using the Varioskan fluorimeter
readout. An algorithm was used for drug combinations where the overall kill rate at any given time is
equal to the kill rate of the drug with the highest kill rate at that given time point (this kill rate is
dependent on the changing of a drug’s concentration and its constant PD parameters [EC50 and Emax]).
Hence, the model assumes that there are no positive or negative PD interactions between the drugs (31).
Bacterial growth and death rates at different drug concentrations were calculated using Pmetrics
GraphPad Prism as follows:
M . tuberculosis count  initial M. tuberculosis count  [1  exp(K  x)]; (1)
where K represents the growth rate per hour and would be a negative value if the bacterial count is
decreasing over time. Each drug concentration generated an independent K value. This value was
normalized to bacterial growth per experiment to avoid interexperimental bias, and thus the growth rate
was divided by the K value to normalize the kill rate. Kill rates at different concentrations are then fitted





where E is the kill rate at any given concentration, Emax is the maximal kill rate of each drug, C is the drug
concentration in mg/liter, and EC50 is the concentration required to achieve a half-maximal kill rate.
Extracellular-grown M. tuberculosis kill rates and EC50 values for RIF, INH, and EMB were derived from
our previous study (22), whereas MXF extracellular EC50 (356 ng/ml) and kill rate (0.23h1) values were
derived in this study (Fig. S5). The LVX extracellular Emax and EC50 values were assumed to be similar to
those for MXF for the purposes of this work.
Modeling parameters. Parameters for RIF, INH, PZA, and EMB were derived from our previous work
(22), whereas parameters for fluoroquinolone drugs were derived from experiments described here.
Table S5 summarizes the parameters used for the simulation with the corresponding references.
We observed a very strong correlation between the growth rate and the corresponding kill rate in all
experiments for all drugs screened. RIF and MXF exhibited similar maximal kill rates that always varied
between 1.6- and 2-fold higher than the growth rate, regardless of whether the latter was fast or slow.
The consistency in the ratio between the growth and kill rates allows the correction of all data to a fixed
growth rate, in all simulations, to reduce output noise while not compromising the final outcomes.
Reported intracellular M. tuberculosis growth rates (also known as doubling times [DT]), including those
reported by us, range from a DT of 21 h to a DT of 48 h (22, 43, 44), while in vivo rodent TB models report
an intracellular DT for M. tuberculosis close to 25 h (45). The reason for the reported variation is not fully
understood but could be partially explained by macrophage modulation of M0/M1/M2 polarization (37).
For the described PDi-based modeling approach, we chose a DT of 21 h for consistency with previous
studies and to avoid bias in cross-study comparisons in the future.
Monte Carlo simulations. Monte Carlo simulations for PK/PD predictions were performed using
Pmetrics with PK parameters derived from the literature. The PK values for MXF were chosen from studies
where MXF was administered with RIF due to the known PK interaction between the two drugs (23, 24).
The PK values for other standard drugs were used as previously described (22).
The models utilized for Monte Carlo simulations here were as described in detail elsewhere (22, 31).
Briefly, the CFU reduction in each simulated patient was driven by exposure to the drug and kill rates of
each drug according to an Emax model (equation 2). Extracellular and intracellular bacilli respond
differently to drug treatment, and both reservoirs were simultaneously simulated for each patient,
resulting in a biexponential decrease in total CFU burden over time (Fig. S3). Overall, the drug kill rate
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(of all drugs in combination) is equal to the rate of the fastest-acting drug at the same time. This is
determined by the epithelial lining fluid (ELF) drug exposure and its intrinsic rate of kill (as defined in
vitro) at any given time point for each drug.
The initial clinical CFU count in each of the 1,000 simulated patient lungs was assumed to be 107
CFU/ml (22). All PK profiles for analysis were assumed to follow a one-compartment model. The
pulmonary levels of drug were assumed to be the driver for activity (where C in equation 2 represents
the drug concentration in the ELF); ELF levels were estimated by using the ELF/serum ratio reported in
the literature, as previously described for RIF, ETB, INH, and PZA, and an ELF ratio of 5.2 was estimated
for MXF (46). The CFU change was recorded over time at fixed intervals of 1 week over a simulated run
time of 4 months (for regimens including MXF, RIF, INH, and PZA) to 6 months (the standard regimen).
It was assumed that a 10 CFU/ml outcome at any given time would indicate culture conversion to be
negative, as previously described (22). The number of patients converting to culture-negative status in
the simulation every week was then recorded for further survival analysis. Table S5 summarizes the
parameters used for the simulation with the corresponding references.
Odds ratios were calculated using IBM SPSS Statistics (version 24; property of IBM Corp.). Data
generated form Monte Carlo simulation from different scenarios were compared head to head, and the
odds ratio with 95% CI was estimated accordingly.
Sensitivity analysis was performed to assess the most influential parameters upon the bacillary
clearance within the simulation (Table S3). The analyses were performed using the FME package (a
Flexible Modeling Environment for Inverse Modeling, Sensitivity, Identifiability and Monte Carlo Analysis)
with R version 3.4.2 (47). Influence of each parameter was expressed in terms of L1-norm and L2-norm
measures, which rank parameters by their effect upon the simulation. The higher the L1-norm or L2-norm
for a given parameter, the higher the sensitivity (48). Sensitivity analysis (Table S3) shows that MXF would
be the main driver of activity in a combination of drugs. This is further corroborated by observing the
changing kill rate over time for each of the partner drugs, which shows that MXF dominates as the fastest
killer throughout the treatment duration, followed by RIF, whereas INH and PZA play a negligible role in
the overall clearance of bacilli (Fig. S5).
Methodological assumptions and limitations. While fluorometry-based measurements of intracel-
lular M. tuberculosis can effectively measure bacillary growth, this approach has a limited dynamic range
when assessing bacillary sterilization over time when measurements fall below the minimum limit of
fluorescence detection. To overcome this issue, high-content (Operetta) imaging was used to more
accurately measure time-dependent bacillary sterilization for specific drugs. With regard to intracellular
M. tuberculosis growth, during the course of this and our other studies, as well as in studies by other
laboratories, we noted a variation in intracellular M. tuberculosis DT, as mention above under “Modeling
Parameters.” To normalize for this in our mathematical modeling, we selected a DT of 21 h throughout.
Furthermore, for the purpose of the mathematical modeling/simulations to predict clinical outcome, in
the absence of evidence to the contrary, we also made a number of assumptions. First, it was assumed
that there is no pharmacological interaction (synergy/additivity/antagonism) between the modeled
drugs; therefore, the clinically observed M. tuberculosis sterilization rate was equivalent to the sterilization
rate of the drug with the fastest sterilization rate. Second, it was also hypothesized that PD interactions
of drugs against intracellular (macrophage) M. tuberculosis measured in in vitro culture were similar to
those in the ELF.
It should be noted that while time-dependent intracellular M. tuberculosis sterilization rates and PDi
PK modeling have been used in this study to predict the clinical activity of fluoroquinolones against TB,
this approach generates dynamic parameters (e.g., EC50 and Emax) that are not suitable for comparison
with traditional static microbiological parameters such as the MIC.
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